Proscia has filed a notice of an exempt offering of securities to raise $15,000,000.00 in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, Proscia is raising up to $15,000,000.00 in new funding. Sources indicate that as part of senior management President and Chief Executive Officer, David West played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.
About Proscia
Proscia is a software company that is accelerating pathologys transformation toward a data-driven discipline. Our Concentric digital pathology platform and powerful AI applications are unlocking new insights that accelerate discovery, improve patient outcomes, and fulfill the promise of precision care. Today, our platform is helping labs worldwide transform from glass to digital, accelerating research and delivering better patient outcomes. More than 6,000 pathologists and researchers use our platform daily at reference labs, academic medical centers, CROs, and 10 of the top 20 pharma leaders. Tomorrow, Proscia will help labs take advantage of a vast and growing set of AI applications built by Proscia and others. Well also help organizations realize the full scale of pathologys potential by leveraging the massive amounts of pathology data being created, managed and curated. Together, well unlock new insights that accelerate discovery, improve patient outcomes, and fulfill the promise of precision care.
To learn more about Proscia, visit http://proscia.com/
Contact:
David West, President and Chief Executive Officer
610-322-3279
https://www.linkedin.com/in/david-west-07b07156/
SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.